Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi




http://scihub22266oqcxt.onion/
suck pdf from google scholar
32532948!ä!32532948

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32532948      Infez+Med 2020 ; 28 (suppl 1): 118-121
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin #MMPMID32532948
  • Viale P; Bartoletti M
  • Infez Med 2020[Jun]; 28 (suppl 1): 118-121 PMID32532948show ga
  • A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). After one week the patient significantly improved and the daily dose of enoxaparin was reduced and definitively discontinued four days later. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). Considering the available information we believe that LMWH may represent a promising treatment for COVID-19 but further well-designed trials are needed to address these points.
  • |Aged[MESH]
  • |Anti-Inflammatory Agents/pharmacology/therapeutic use[MESH]
  • |Anticoagulants/pharmacology/*therapeutic use[MESH]
  • |Antihypertensive Agents/therapeutic use[MESH]
  • |Azithromycin/administration & dosage/therapeutic use[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Drug Treatment[MESH]
  • |Combined Modality Therapy[MESH]
  • |Coronavirus Infections/*complications/diagnostic imaging/drug therapy/therapy[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Enoxaparin/pharmacology/*therapeutic use[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/administration & dosage/therapeutic use[MESH]
  • |Hypertension/complications/drug therapy[MESH]
  • |Male[MESH]
  • |Oxygen Inhalation Therapy[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications/diagnostic imaging/drug therapy/therapy[MESH]
  • |Thrombophilia/*drug therapy/etiology[MESH]
  • |Tomography, X-Ray Computed[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box